Information  X 
Enter a valid email address

Company Name matching 'ProMIS Neurosciences Inc'

Date
Time Source
Company
Announcement
19 Jun 2019 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Appoints Renowned Parkinson’s Disease Expert Dr. C. Warren Olanow to Scientific Advisory Board
05 Jun 2019 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Presents Lead Program for Alzheimer’s Disease at Prestigious Keystone Symposia Scientific Conference
29 May 2019 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences’ Eugene Williams to Present at JLABS’ Conference on Innovations in Neurodegenerative Diseases
28 May 2019 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Identifies Novel Antibodies for Alzheimer’s Disease with Selectivity for the Neurotoxic Form of Tau
14 May 2019 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Announces First Quarter 2019 Results
23 Apr 2019 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences to Participate in the Think Equity Investor Conference
21 Mar 2019 7:13 pm GNW     ProMIS Neurosciences Inc. Aducanumab Failure: Selectivity for the Toxic Oligomer is Essential to Treating Root Cause of Alzheimer’s Disease
19 Mar 2019 11:30 am GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences to Present Data for Potential Best-in-Class Antibody Candidates for Parkinson’s Disease at AD/PD™ 2019 Conference
15 Mar 2019 11:30 am GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Fiscal Year 2018 Annual Results
21 Feb 2019 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Adds Pharmaceutical Leader Timothy Rothwell to Board of Advisors
12 Feb 2019 12:30 pm GNW     ProMIS Neurosciences Inc. Parkinson’s Disease: ProMIS Neurosciences Identifies Several Antibody Drug Candidates Showing Best-in-Class Selectivity for Toxic Forms of Alpha-Synuclein Compared to other Therapeutic Antibodies in Development
31 Jan 2019 12:30 pm GNW     ProMIS Neurosciences Inc. Selectivity for the Toxic Oligomer Essential to Treating Root Cause of Alzheimer’s Disease
23 Jan 2019 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Completes Private Placement of Units
17 Jan 2019 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences to Participate in NobleCon15 and CanTech Investment Conferences
18 Dec 2018 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences to Present at Sachs Associates Neuroscience Innovation Forum and China [email protected]
17 Dec 2018 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Appoints Renowned Neuroscientist, Dr. Rudolph Tanzi, to Scientific Advisory Board
20 Nov 2018 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Issues Year-to-Date Update, Highlighting 2018 Accomplishments
13 Nov 2018 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Announces Third Quarter 2018 Results
06 Nov 2018 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Discusses Critical Importance of Selectively Targeting the Root Cause of Alzheimer’s Disease
31 Oct 2018 11:30 am GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Identifies Novel Targets on Tau Protein Involved in the Development of Alzheimer’s Disease and Other Dementias
11 Oct 2018 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Identifies Novel Antibody Drug Candidates for Parkinson’s Disease
13 Sep 2018 12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer
  12:30 pm GNW     ProMIS Neurosciences Inc. ProMIS Neurosciences Appoints James Kupiec, MD as Chief Medical Officer


Company Announcements Archive »

 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t